Nexstim Plc: Amendment of the terms of stock options programs and warrants
Company announcement, inside information, Helsinki, 7 April 2021 at 8.30 PM (EEST)
Nexstim Plc: Amendment of the terms of stock options programs and warrants
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) has completed a subscription rights issue which ended on 29 March 2021 in Sweden and on 31 March 2021 in Finland. With reference to the Company announcement published earlier today the Company has also decided on directed share issue. In relation to these rights issues the Board of Directors has today on 7 April 2021 resolved to reduce the share subscription prices of the Company’s stock option programs 2016B-C, 2018A-B and 2020A-C as well as the exercise prices of the outstanding warrant agreements i.e. special rights to shares.
According to the terms and conditions of the stock option programs and the warrant agreements, the share subscription prices shall be amended so that the share subscription price of such stock option programs or warrants is comparable to the price prior to the aforementioned rights issues. Therefore, the subscription prices shall be amended as follows:
|Option plan/ warrant||Subscription price per share before amendment||New subscription price per share|
|Optionplan 2016B||EUR 0.23||EUR 0.18|
|Optionplan 2016C||EUR 0.30||EUR 0.23|
|Optionplan 2018A||EUR 0.07||EUR 0,05|
|Optionplan 2018B||EUR 0.01||EUR 0.01|
|Optionplan 2020A||EUR 0.03||EUR 0.02|
|Optionplan 2020B||EUR 0.07||EUR 0.07|
|Kreos warrants||EUR 0.41||EUR 0.32|
·to be decided 2022
Regarding option programs 2020A-C the Board of Directors further decided to amend the amounts of option in the option program resolved on June 10, 2020 aimed at the personnel, management and other interest groups of Nexstim Plc and its subsidiaries, by virtue of an authorization granted by Extraordinary General Meeting of Shareholders of the Company on 1 March 2021 as follows:
The maximum total number of stock options 2020 to be issued is 58,500,000 and they entitle their owners to subscribe for a maximum total of 58,500,000 new or treasury shares in the Company. The Board of Directors will resolve whether new or treasury shares are given to subscribers. Taking into account aforementioned subscription rights issue and direct issue, the number of shares subscribed by exercising stock options 2020 corresponds to a maximum total of 8.10 per cent of all shares in the Company after the potential share subscription, if 58,500,000 new shares are issued. For the avoidance of doubt, with this amendment the number of options shall increase by 19,500,000 option and shares.
The Company has a weighty financial reason for the issue of stock options, since the stock options are intended to form part of the incentive and commitment program for the personnel, management and other interest groups. The purpose of the stock options is to encourage the personnel, management and other interest groups to work and co-operate on a long-term basis to increase shareholder value. The purpose of the stock options is also to commit the personnel, management and other interest groups to the Company.
Of the stock options after the amendment, 19,500,000 are part of stock options 2020A; 19,500,000 stock options 2020B; and 19,500,000 stock options 2020C. The share subscription period for stock options 2020A will be July 1, 2022—December 15, 2027; for stock options 2020B: July 1, 2023—December 15, 2028; and for stock options 2020C: July 1, 2024—December 15, 2029
All stock options will be issued gratuitously. New share subscription prices for stock options 2020A and 2020B are presented in the table above.
The share subscription price for stock options 2020C is the trade volume weighted average quotation of the share on Nasdaq First North Growth Market Finland during twenty (20) trading days following the release date of the Company´s Financial Statements of the year 2021.
The share subscription price will be credited to the reserve for the Company’s invested unrestricted equity. The shares must be paid upon subscription. The above changes shall be taken into account in the subscription prices
The amended terms of the option rights and warrants are available on the Company's website www.nexstim.com/investors/share-information/.
Leena Niemistö, Chair of the Board of Directors
Further information is available on the website www.nexstim.com, or by contacting:
Leena Niemistö, Chair
+358 9 2727 170
Erik Penser Bank AB (Certified Adviser)
+46 8 463 83 00
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Correction: REGARDING DRAFT ALTERNATIVE RESOLUTION SUBMITTED TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS16.4.2021 14:49:32 CEST | Press release
Correction: the number of shares indicated – 380.396.585 and declared dividends per share – 0,0198 EUR. On 15 April 2021 AB “Klaipėdos nafta” (hereinafter – Company) received a proposal from the Ministry of Energy of the Republic of Lithuania (hereinafter referred to as the Shareholder), that executes the rights of the Shareholder – the Republic of Lithuania that owns 275 687 444 ordinary registered shares, making 72,45 per cent of the total amount of the Company’s shares, on an alternative draft resolution of the issue on the agenda of the ordinary registered meeting of shareholders of the Company to be convened on 30 April 2021. Following paragraphs 3, 4 and 5 of Article 25 of the Law on Companies of the Republic of Lithuania, the Shareholder as the person exercising the right to propose draft resolutions of the Company’s General Meeting, holding shares that grant at least 1/20 of all the votes, proposes to approve the following draft resolution of the fourth item on the agenda of th
Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)16.4.2021 14:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 16 April 2021 at 3:30 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 15 April 2021 above five (5) per cent of Sampo plc’s total voting rights. In addition, the disclosure obligation arose due to the number of Sampo A shares owned directly or indirectly by BlackRock, Inc. and its funds increasing above 5 per cent. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions
CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 1016.4.2021 12:45:00 CEST | Press release
Allentown, April 16, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 10 ALLENTOWN, PA, April 16, 2021 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its first quarter 2021 results after the market closes on Monday, May 10, 2021. In conjunction with the news release, management will host a conference call on Tuesday, May 11, at 9:00 a.m. Eastern Time. The conference call numbers are 800-774-6070 or 630-691-2753 and the passcode for both is 7265208#. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor section of the CrossAmerica website (www.crossamericapartners.com). To listen to the audio webcast, go to https://caplp.gcs-web.com/webcasts-presentations https://caplp.gcs-web.com/webcasts-presentations. A
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD16.4.2021 11:00:00 CEST | Press release
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression. Oladele Adebogun M.D. said, “I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the number of pat
RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS16.4.2021 10:08:23 CEST | Press release
Auction date2021-04-16Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 400Volume offered, SEK mln4,000Volume bought, SEK mln750Number of bids12Number of accepted bids3Average yield0.367 %Lowest accepted yield0.367 %Highest yield0.368 %% accepted at lowest yield 65.00 Auction date2021-04-16Loan1053Coupon3.50 %ISIN-codeSE0002829192Maturity2039-03-30Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,400Volume bought, SEK mln500Number of bids5Number of accepted bids2Average yield0.696 %Lowest accepted yield0.693 %Highest yield0.698 %% accepted at lowest yield 100.00 Auction date2021-04-16LoanREGS Kingdom of SwedenCoupon0.125 %ISIN-codeXS2226974504Maturity2030-09-09Tendered volume, SEK mln250 +/- 250Volume offered, SEK mln600Volume bought, SEK mln250Number of bids6Number of accepted bids3Average yield0.287 %Lowest accepted yield0.281 %Highest yield0.291 %% accepted at lowest yield 50.00
Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®16.4.2021 09:00:00 CEST | Press release
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy. The trial is originated by the principal investigator of the trial, Dr Michael Häggman, Associate Professor at the Department of Surgical Sciences in Urology, Uppsala University Hospital. The study is planned to start in mid of this year and it will enroll 10- 15 patients to be treated with NZ-DTX prior to planned surgery. “The NanoZolid technology is suitable to combine with the MRI/TRUS injection technique for a high precision intratumoral delivery of NZ-DTX Depot. Treating patients prior to removal of the prostate gland will provide exhaustive information with regards to local effects in the tumor and surrounding tissue”, commented Dr Michael Häggman. “We are very pleased
Notice of Annual General Meeting in Eolus Vind AB (publ)16.4.2021 08:30:00 CEST | Press release
Hässleholm, Sweden, April 16th, 2021 The shareholders of Eolus Vind AB (publ) are hereby invited to attend the Annual General Meeting (“AGM”) to be held on May 19, 2021. The Board of Directors has decided that the AGM should be conducted by way of postal vote pursuant to temporary legislation being in effect in 2021. This means that the AGM will be held without the physical presence of shareholders, representatives or third parties. The shareholders will therefore only be able to exercise their voting rights by postal voting in the manner prescribed below. An address in which the CEO Per Witalisson comments on Eolus’ operations and any questions submitted to the company will be published on Eolus’s website www.eolusvind.com on May 19, 2021. Information on the resolutions passed at the AGM will be disclosed on May 19, 2021, when the outcome of the postal voting has been confirmed. Right to attend Shareholders who wish to attend the AGM must be recorded in the share register maintained b